1
|
Zhao T, Liu S, Ma X, Shuai Y, He H, Guo T, Huang W, Wang Q, Liu S, Wang Z, Gong G, Huang L. Lycium barbarum arabinogalactan alleviates intestinal mucosal damage in mice by restoring intestinal microbes and mucin O-glycans. Carbohydr Polym 2024; 330:121882. [PMID: 38368089 DOI: 10.1016/j.carbpol.2024.121882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Revised: 01/25/2024] [Accepted: 01/26/2024] [Indexed: 02/19/2024]
Abstract
Structurally defined arabinogalactan (LBP-3) from Lycium barbarum have effect on improving intestinal barrier function. However, whether its intestinal barrier function depended on the changes of intestinal mucin O-glycans have not been investigated. A dextran sodium sulfate-induced acute colitis mouse model was employed to test prevention and treatment with LBP-3. The intestinal microbiota as well as colonic mucin O-glycan profiles were analyzed. Supplementation with LBP-3 inhibited harmful bacteria, including Desulfovibrionaceae, Enterobacteriaceae, and Helicobacteraceae while significantly increased the abundance of beneficial bacteria (e.g., Lachnospiraceae, Ruminococcaceae, and Lactobacillaceae). Notably, LBP-3 augmented the content of neutral O-glycans by stimulating the fucosylation glycoforms (F1H1N2 and F1H2N2), short-chain sulfated O-glycans (S1F1H1N2, S1H1N2, and S1H2N3), and sialylated medium- and long-chain O-glycans (F1H2N2A1, H2N3A1, and F1H3N2A1). In summary, we report that supplement LBP-3 significantly reduced pathological symptoms, restored the bacterial community, and promoted the expression of O-glycans to successfully prevent and alleviate colitis in a mouse model, especially in the LBP-3 prevention testing group. The underlying mechanism of action was investigated using glycomics to better clarify which the structurally defined LBP-3 were responsible for its beneficial effect against ulcerative colitis and assess its use as a functional food or pharmaceutical supplement.
Collapse
Affiliation(s)
- Tong Zhao
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Sining Liu
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Xiaoran Ma
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Yutong Shuai
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Houde He
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Tongyi Guo
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Wenqi Huang
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Qian Wang
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Shan Liu
- Tianren Goji Biotechnology Co., Ltd, Ningxia, China
| | - Zhongfu Wang
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China
| | - Guiping Gong
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China.
| | - Linjuan Huang
- Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an 710069, China.
| |
Collapse
|
2
|
Guan H, Ke W, Yan Y, Shuai Y, Li X, Ran Q, Yang Z, Wang X, Cai Y, Zhang X. Screening of natural lactic acid bacteria with potential effect on silage fermentation, aerobic stability and aflatoxin B1 in hot and humid area. J Appl Microbiol 2020; 128:1301-1311. [DOI: 10.1111/jam.14570] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 12/21/2019] [Accepted: 12/23/2019] [Indexed: 01/03/2023]
Affiliation(s)
- H. Guan
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| | - W. Ke
- State Key Laboratory of Grassland and Agro‐Ecosystems School of Life Sciences Lanzhou University Lanzhou China
- Probiotics and Biological Feed Research Center Lanzhou University Lanzhou China
| | - Y. Yan
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| | - Y. Shuai
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| | - X. Li
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| | - Q. Ran
- Institute of Grass Science Chongqing Academy of Animal Husbandry Chongqing China
| | - Z. Yang
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| | - X. Wang
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| | - Y. Cai
- Japan International Research Center for Agricultural Science (JIRCAS) Tsukuba Ibaraki Japan
| | - X. Zhang
- Animal Science and Technology College Sichuan Agricultural University Chengdu China
| |
Collapse
|
3
|
Shen XX, Wang JP, Chen YY, An YL, Gong QH, Zhang B, Hong J, Shuai Y, Zhao F, Li H, Li GW. [Subjects with impaired glucose tolerance returned to normal glucose status for six years had lower long-term risk of diabetes: 20 years follow up of Daqing diabetes prevention study]. Zhonghua Nei Ke Za Zhi 2019; 58:372-376. [PMID: 31060146 DOI: 10.3760/cma.j.issn.0578-1426.2019.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Objective: To explore the influence of lifestyle intervention on long-term diabetes in subjects with impaired glucose tolerance (IGT) returned to normal glucose tolerance (NGT) within 6 years. Methods: A total of 577 subjects (aged 25-74 years old) with IGT in Daqing were enrolled and randomly assigned to control, and diet, exercise and diet plus exercise groups in a six-year intervention trial in 1986. Subjects who were non-diabetic at the end of the intervention were followed up for additional 14 years. Results: Among all the subjects, 41.38% of them who had returned to NGT from IGT within 6 years maintained NGT status after 20 years, and had a lower incidence of diabetes than subjects maintained IGT status (46.55% vs. 75.25%). Of note, in the intervention group, the percentage of participants developed diabetes in the NGT subjects was significantly lower than that in the IGT group (43.71% vs. 76.25%) after 20 years. There was high long-term risk for diabetes in the IGT subjects after the adjustment of age, sex and baseline glucose (HR=1.81, 95%CI 1.27-2.58, P=0.001), whereas in the non-intervention group, no significant difference could be viewed in long-term diabetic risk between subjects maintained IGT status and those returned to NGT (71.43% vs. 65.22%) after adjusting of the same confounders (HR=1.03, 95%CI 0.45-2.35, P=0.94). Conclusions: IGT subjects who had returned to NGT in early years had lower risk for future diabetes than those who remained IGT. However, this beneficial effect could only be viewed in the intervention group, but not in the non-intervention group.
Collapse
Affiliation(s)
- X X Shen
- Center of Endocrinology and Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - J P Wang
- Department of Cardiology, Da Qing First Hospital, Daqing 163000, China
| | - Y Y Chen
- Center of Endocrinology and Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - Y L An
- Center of Endocrinology and Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - Q H Gong
- Center of Endocrinology and Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - B Zhang
- Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China
| | - J Hong
- Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China
| | - Y Shuai
- Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China
| | - F Zhao
- Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China
| | - H Li
- Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China
| | - G W Li
- Center of Endocrinology and Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China; Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China
| |
Collapse
|
4
|
Zhang GH, Zhong QY, Gou XX, Fan EX, Shuai Y, Wu MN, Yue GJ. Seven genes for the prognostic prediction in patients with glioma. Clin Transl Oncol 2019; 21:1327-1335. [PMID: 30762207 DOI: 10.1007/s12094-019-02057-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 01/30/2019] [Indexed: 12/15/2022]
Abstract
PURPOSE Glioma is a common malignant tumor of the central nervous system, which is characterized by a low cure rate, high morbidity, and high recurrence rate. Consequently, it is imperative to explore some indicators for prognostic prediction in glioma. METHODS We obtained glioma data from The Cancer Genome Atlas (TCGA). Differentially expressed genes (DEGs) were obtained by R software from TCGA data sets. Through Cox regression analysis, risk scores were obtained to assess the weighted gene-expression levels, which could predict the prognosis of patients with glioma. The validity and the prognostic value of this model in glioma were confirmed by the manifestation of receiver-operating characteristic (ROC) curves, area under the curve (AUC), and 5-year overall survival (OS). RESULTS In total, 920 DEGs of transcriptome genes in glioma were extracted from the TCGA database. We identified a novel seven-gene signature associated with glioma. Among them, AL118505.1 and SMOC1 were positively related to the 5-year OS of patients with glioma, showing a better prognosis for glioma; however, RAB42, SHOX2, IGFBP2, HIST1H3G, and IGF2BP3 were negatively related to 5-year OS, displaying a worse prognosis. In addition, according to risk scores, AL118505.1 was also a protective factor, while others were risk factors. Furthermore, the expression levels of SHOX2, IGFBP2, and IGF2BP3 were significantly positively correlated with glioma grades. Receiver-operating characteristic (ROC) curve assessed the accuracy and sensitivity of the gene signature. Each of the seven genes for patients with the distribution of the risk score was presented in the heat map. CONCLUSION We identified a novel seven-gene signature in patients with glioma, which could be used as a predictor for the prognosis of patients with glioma in the future.
Collapse
Affiliation(s)
- G-H Zhang
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China.
| | - Q-Y Zhong
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China
| | - X-X Gou
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China
| | - E-X Fan
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China
| | - Y Shuai
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China
| | - M-N Wu
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China
| | - G-J Yue
- Department of Head and Neck Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, People's Republic of China.
| |
Collapse
|
5
|
Su X, Liao L, Shuai Y, Jing H, Liu S, Zhou H, Liu Y, Jin Y. MiR-26a functions oppositely in osteogenic differentiation of BMSCs and ADSCs depending on distinct activation and roles of Wnt and BMP signaling pathway. Cell Death Dis 2015; 6:e1851. [PMID: 26247736 PMCID: PMC4558512 DOI: 10.1038/cddis.2015.221] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 07/01/2015] [Accepted: 07/02/2015] [Indexed: 12/12/2022]
Abstract
MicroRNAs (miRNAs) emerge as important regulators of stem cell lineage commitment and bone development. MiRNA-26a (miR-26a) is one of the important miRNAs regulating osteogenic differentiation of both bone marrow-derived mesenchymal stem cells (BMSCs) and adipose tissue-derived mesenchymal stem cells (ADSCs). However, miR-26a functions oppositely in osteogenic differentiation of BMSCs and ADSCs, suggesting distinct post-transcriptional regulation of tissue-specific MSC differentiation. However, the molecular basis is largely unknown. Here, we report that the function of miR-26a is largely depended on the intrinsic signaling regulation network of MSCs. Using bioinformatics and functional assay, we confirmed that miR-26a potentially targeted on GSK3β and Smad1 to regulate Wnt and BMP signaling pathway. Overall comparative analysis revealed that Wnt signaling was enhanced more potently and played a more important role than BMP signaling in osteogenic differentiation of BMSCs, whereas BMP pathway was more essential for promoting osteogenic differentiation of ADSCs. The distinct activation pattern and role of signaling pathways determined that miR-26a majorly targeted on GSK3β to activate Wnt signaling for promoting osteogenic differentiation of BMSCs, whereas it inhibited Smad1 to suppress BMP signaling for interfering with the osteogenic differentiation of ADSCs. Taken together, our study demonstrated that BMSCs and ADSCs applied different signaling pathway to facilitate their osteogenic differentiation, which determined the inverse function of miR-26a. The distinct transcriptional regulation and post-transcriptional regulation network suggested the intrinsic molecular differences between tissue-specific MSCs and the complexity in MSC research and MSC-based cell therapy.
Collapse
Affiliation(s)
- X Su
- 1] Department of Orthodontics, Stomatology Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710004, China [2] State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China [3] Institute of Neurobiology, Environment and Genes Related to Diseases, Key Laboratory of Education Ministry, Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, China
| | - L Liao
- 1] State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China [2] Research and Development Center for Tissue Engineering, Fourth Military Medical University, Xi'an, Xi'an, Shaanxi 710032, China [3] State Key Laboratory of Military Stomatology, Department of Oral Histology and pathology, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - Y Shuai
- 1] State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China [2] Research and Development Center for Tissue Engineering, Fourth Military Medical University, Xi'an, Xi'an, Shaanxi 710032, China [3] State Key Laboratory of Military Stomatology, Department of Oral Histology and pathology, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - H Jing
- 1] State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China [2] Research and Development Center for Tissue Engineering, Fourth Military Medical University, Xi'an, Xi'an, Shaanxi 710032, China [3] State Key Laboratory of Military Stomatology, Department of Oral Histology and pathology, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - S Liu
- 1] State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China [2] Research and Development Center for Tissue Engineering, Fourth Military Medical University, Xi'an, Xi'an, Shaanxi 710032, China [3] State Key Laboratory of Military Stomatology, Department of Oral Histology and pathology, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
| | - H Zhou
- Department of Orthodontics, Stomatology Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710004, China
| | - Y Liu
- Institute of Neurobiology, Environment and Genes Related to Diseases, Key Laboratory of Education Ministry, Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, China
| | - Y Jin
- 1] State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China [2] Research and Development Center for Tissue Engineering, Fourth Military Medical University, Xi'an, Xi'an, Shaanxi 710032, China
| |
Collapse
|
6
|
Yue Q, Yulong G, Liting Q, Shuai Y, Delong L, Yubao L, Lili J, Sidang L, Xiaomei W. Mutations in and Expression of the Tumor Suppressor Gene p53 in Egg-Type Chickens Infected With Subgroup J Avian Leukosis Virus. Vet Pathol 2014; 52:1052-6. [PMID: 25445321 DOI: 10.1177/0300985814560232] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To investigate the molecular mechanisms of the oncogenic effects of avian leukosis virus subgroup J (ALV-J), we examined mutations in and the expression of p53 in the myelocytomas distributed in the liver, spleen, trachea, and bone marrow, as well as in fibrosarcomas in the abdominal cavity and hemangiomas in skin from chickens that were naturally or experimentally infected with ALV-J. Two types of mutations in the p53 gene were detected in myelocytomas of both the experimentally infected and the naturally infected chickens and included point mutations and deletions. Two of the point mutations have not been reported previously. Partial complementary DNA clones with a 122-bp deletion in the p53 gene ORF and a 15-bp deletion in the C-terminus were identified in the myelocytomas. In addition, moderate expression of the mutant p53 protein was detected in the myelocytomas that were distributed in the liver, trachea, spleen, and bone marrow. Mutant p53 protein was not detected in the subcutaneous hemangiomas or in the abdominal fibrosarcomas associated with natural and experimental ALV-J infection, respectively. These results identify mutations associated with abnormal expression of p53 in ALV-J-associated myelocytomas, suggesting a role in tumorigenesis.
Collapse
Affiliation(s)
- Q Yue
- Division of Avian infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang, P.R. China College of Animal Husbandry and Veterinary, Liao Ning Medical University, P.R. China College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Taian, P.R. China Liaocheng Vocational and Technical College, Liaocheng, P.R. China
| | - G Yulong
- Division of Avian infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang, P.R. China
| | - Q Liting
- Division of Avian infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang, P.R. China
| | - Y Shuai
- Division of Avian infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang, P.R. China
| | - L Delong
- Division of Avian infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang, P.R. China College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Taian, P.R. China
| | - L Yubao
- School of Agriculture, Liaocheng University, Liaocheng, P.R. China
| | - J Lili
- College of Animal Husbandry and Veterinary, Liao Ning Medical University, P.R. China
| | - L Sidang
- College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Taian, P.R. China
| | - W Xiaomei
- Division of Avian infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang, P.R. China Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou, 225009
| |
Collapse
|
7
|
Wu CG, Li P, Luo WB, Meng J, Sun XY, Shuai Y, Zhang WL. Synthesis, property and application of PZT/P(VDF-TrFE) composite film fabricated on polyimide substrate. ACTA ACUST UNITED AC 2014. [DOI: 10.1179/1432891714z.000000000409] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Affiliation(s)
- C. G. Wu
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| | - P. Li
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| | - W. B. Luo
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| | - J. Meng
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| | - X. Y. Sun
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| | - Y. Shuai
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| | - W. L. Zhang
- State Key Lab of Electronic Thin Films and Integrated DevicesUniversity of Electronic Science and Technology of China, Chengdu 610054, China
| |
Collapse
|
8
|
Zhao J, Lu Y, Zhao X, Yao X, Shuai Y, Huang C, Wang L, Jeong SH, Zhong Y. Dissociation ofrugose-dependent short-term memory component from memory consolidation inDrosophila. Genes, Brain and Behavior 2013; 12:626-32. [DOI: 10.1111/gbb.12056] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2013] [Revised: 05/22/2013] [Accepted: 06/14/2013] [Indexed: 11/28/2022]
Affiliation(s)
- J. Zhao
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - Y. Lu
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - X. Zhao
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - X. Yao
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - Y. Shuai
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - C. Huang
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - L. Wang
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | - S. H. Jeong
- School of Life Sciences; Tsinghua University; Beijing; PR China
| | | |
Collapse
|
9
|
Bhargava R, Klein ME, Shuai Y, Brufsky AM, Puhalla SL, Jankowitz R, Dabbs DJ. Abstract P6-07-02: Prediction of onco type DX® recurrence score using pathology generated equations. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Oncotype DX® is a quantitative reverse transcription polymerase chain reaction based assay that has been shown to have prognostic and predictive value in estrogen receptor (ER) positive breast cancers. The result is reported as a recurrence score (RS) ranging from 0–100, divided into low risk (<18), intermediate risk (18–30), and high risk (≥31) categories. Prior studies have shown that RS is influenced by ER and progesterone receptor (PR) expression, HER2 status, proliferation index, and tumor grade. Our pilot study showed that RS can be predicted by an equation incorporating standard morpho-immunohistologic variables (referred to as Original Magee Equation; Mod Pathol. 2008;21:1255–1261).
METHODS: Using a dataset of 817 cases, we formulated three additional equations to predict the RS category for an independent set of 255 cases. Three models were built based on different hypotheses and data availability and are represented below.
New Magee Equation 1 (nME1): RS = 15.31385 + Nottingham score*1.4055+ ER H-score*(−0.01924) + PR H-score*(−0.02925) + (0 for HER2 negative, 0.77681 for equivocal, 11.58134 for HER2 positive) + Tumor size*0.78677 + KI67 index*0.13269.
New Magee Equation 2 (nME2): RS = 18.8042+ Nottingham score*2.34123 + ER H-score*(−0.03749) + PR H-score*(−0.03065) + (0 for HER2 negative, 1.82921 for equivocal, 11.51378 for HER2 positive) + Tumor size*0.04267.
New Magee Equation 3 (nME3): RS = 24.30812+ ER H-score*(−0.02177) + PR H-score*(−0.02884) + (0 for HER2 negative, 1.46495 for equivocal, 12.75525 for HER2 positive) + KI-67*0.18649.
RESULTS: The concordance between the risk category of oncotype DX® and our equations was 55.8%, 59.4%, and 54.4% for nME1, nME2, and nME3 respectively. With exclusion of the intermediate risk categories for both the actual RS and estimated RS, the concordance for each equation increased to more than 95%, reflecting the very low two step discordance (100% {76/76}, 98.6% {75/76}, and 98.7% {79/80} for nME1, nME2, and nME3 respectively). Even when the estimated RS fell in the intermediate category with any of the equations, the actual RS was either intermediate or low in more than 85% of the cases. The Pearson correlation coefficient between estimated and actual RS was similar for each of the equations (0.61661, 0.60386 and 0.59407 for nME1, nME2 and nME3, respectively).
CONCLUSIONS: Any of the 3 equations can be used to estimate the RS depending on available data. If the estimated RS is clearly high or low, the oncologists should not expect a dramatically different result from oncotype DX®, and the oncotype DX® test may not be needed. Conversely, an oncotype DX® result that is dramatically different from what is expected based on standard morpho-immunohistologic variables should be thoroughly investigated.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-02.
Collapse
Affiliation(s)
- R Bhargava
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - ME Klein
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - Y Shuai
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - AM Brufsky
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - SL Puhalla
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - R Jankowitz
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - DJ Dabbs
- Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA
| |
Collapse
|
10
|
Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol 2011; 22:2482-2488. [PMID: 21363880 PMCID: PMC3200222 DOI: 10.1093/annonc/mdr002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2010] [Revised: 12/28/2010] [Accepted: 12/31/2010] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer. PATIENTS AND METHODS Patients received pemetrexed on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and cetuximab in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. RESULTS Thirty-two patients were enrolled. The maximum tolerated dose of pemetrexed was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. CONCLUSION The addition of pemetrexed 500 mg/m(2) to cetuximab and radiotherapy is recommended for further study in not previously irradiated patients.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/genetics
- Carcinoma, Squamous Cell/radiotherapy
- Cetuximab
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Female
- Glutamates/administration & dosage
- Glutamates/adverse effects
- Guanine/administration & dosage
- Guanine/adverse effects
- Guanine/analogs & derivatives
- Head and Neck Neoplasms/drug therapy
- Head and Neck Neoplasms/genetics
- Head and Neck Neoplasms/radiotherapy
- Humans
- Male
- Methylenetetrahydrofolate Reductase (NADPH2)/genetics
- Middle Aged
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/radiotherapy
- Pemetrexed
- Polymorphism, Genetic
- Squamous Cell Carcinoma of Head and Neck
- Thymidylate Synthase/genetics
Collapse
Affiliation(s)
- A Argiris
- University of Pittsburgh Cancer Institute; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine; Department of Otolaryngology.
| | - M V Karamouzis
- Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine
| | - R Smith
- University of Pittsburgh Cancer Institute; Department of Radiation Oncology
| | - A Kotsakis
- Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine
| | - M K Gibson
- University of Pittsburgh Cancer Institute; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine
| | - S Y Lai
- Department of Otolaryngology
| | - S Kim
- University of Pittsburgh Cancer Institute; Department of Otolaryngology
| | - B F Branstetter
- Department of Otolaryngology; Department of Radiology, University of Pittsburgh School of Medicine
| | - Y Shuai
- University of Pittsburgh Cancer Institute
| | - M Romkes
- University of Pittsburgh Cancer Institute; Division of Clinical Pharmacology, Department of Medicine, University of Pittsburgh School of Medicine
| | - L Wang
- Department of Otolaryngology; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, USA
| | - J R Grandis
- University of Pittsburgh Cancer Institute; Department of Otolaryngology
| | - R L Ferris
- University of Pittsburgh Cancer Institute; Department of Otolaryngology; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, USA
| | - J T Johnson
- University of Pittsburgh Cancer Institute; Department of Otolaryngology
| | - D E Heron
- University of Pittsburgh Cancer Institute; Department of Radiation Oncology
| |
Collapse
|
11
|
Tarhini AA, Edington H, Butterfield LH, Sinha M, Moschos SJ, Tawbi H, Shuai Y, Shipe-Spotloe J, Simonettta M, Milburn C, Horak M, Sander C, Kirkwood JM. Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: Immunogenicity and biomarker analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8536] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, Li H, Li H, Jiang Y, Shuai Y, Zhang B, Zhang J, Gerzoff RB, Roglic G, Hu Y, Li G, Bennett PH. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011; 54:300-7. [PMID: 21046360 DOI: 10.1007/s00125-010-1948-9] [Citation(s) in RCA: 134] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2010] [Accepted: 09/20/2010] [Indexed: 12/18/2022]
Abstract
AIMS/HYPOTHESIS We determined the effects of 6 years of lifestyle intervention in persons with impaired glucose tolerance (IGT) on the development of retinopathy, nephropathy and neuropathy over a 20 year period. METHODS In 1986, 577 adults with IGT from 33 clinics in Da Qing, China were randomly assigned by clinic to a control group or one of three lifestyle intervention groups (diet, exercise, and diet plus exercise). Active intervention was carried out from 1986 to 1992. In 2006 we conducted a 20 year follow-up study of the original participants to compare the incidence of microvascular complications in the combined intervention group vs the control group. RESULTS Follow-up information was obtained on 542 (94%) of the 577 original participants. The cumulative incidence of severe retinopathy was 9.2% in the combined intervention group and 16.2% in the control group (p = 0.03, log-rank test). After adjusting for clinic and age, the incidence of severe retinopathy was 47% lower in the intervention group than the control group (hazard rate ratio 0.53, 95% CI 0.29-0.99, p = 0.048). No significant differences were found in the incidence of severe nephropathy (hazard rate ratio 1.05, 95% CI 0.16-7.05, intervention vs control, p = 0.96) or in the prevalence of neuropathy (8.6% vs 9.1%, p = 0.89) among the 20 year survivors. CONCLUSIONS/INTERPRETATION Lifestyle intervention for 6 years in IGT was associated with a 47% reduction in the incidence of severe, vision-threatening retinopathy over a 20 year interval, primarily due to the reduced incidence of diabetes in the intervention group. However, similar benefits were not seen for nephropathy or neuropathy.
Collapse
Affiliation(s)
- Q Gong
- Department of Endocrinology, China-Japan Friendship Hospital, Yinghua Dong Lu, Chaoyang District, Beijing, 100029, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Tarhini AA, Moschos SJ, Tawbi H, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8524] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, Kim SW, Grandis JR, Ferris RL, Johnson JT, Argiris A. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol 2010; 21:2278-2283. [PMID: 20430907 DOI: 10.1093/annonc/mdq226] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [¹⁸F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. PATIENTS AND METHODS We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy. RESULTS Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002). CONCLUSIONS A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.
Collapse
Affiliation(s)
- V A Passero
- Division of Hematology-Oncology, Department of Medicine
| | | | - Y Shuai
- The University of Pittsburgh Cancer Institute Biostatistics Facility
| | - D E Heron
- Department of Radiation Oncology, University of Pittsburgh and Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
| | - M K Gibson
- Division of Hematology-Oncology, Department of Medicine
| | - S Y Lai
- Department of Otolaryngology
| | - S W Kim
- Department of Otolaryngology
| | | | | | | | - A Argiris
- Division of Hematology-Oncology, Department of Medicine; Department of Otolaryngology.
| |
Collapse
|
15
|
Zhou C, Shuai Y, Yi D, Sun Z, Zhang J. Characterization and primary function study of a novel gene HMGB4 in human testis. Fertil Steril 2009. [DOI: 10.1016/j.fertnstert.2009.07.1477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Sehgal R, McHayleh W, Lembersky BC, Schlesselman JJ, Evans S, Shuai Y, Winters S, Ramanathan RK. Survival differences in colorectal cancer (CRC) on the basis of race: University of Pittsburgh Medical Center (UPMC) experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Owonikoko TK, Ramalingam S, Forster J, Shuai Y, Evans T, Gooding WE, Sulecki M, Belani CP. Phase II study of irinotecan and paclitaxel for patients with recurrent small cell lung cancer (SCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18011 Background: Recurrent SCLC has a poor prognosis and is devoid of treatment options that improve overall survival. Irinotecan and paclitaxel are both active agents against SCLC, and have synergistic preclinical interactions. We conducted a phase II study to evaluate the efficacy and safety of the combination of irinotecan and paclitaxel for patients with recurrent SCLC. Methods: Patients with SCLC who relapsed following one prior chemotherapy regimen were eligible. Other pertinent inclusion criteria were: ECOG performance status 0–2, adequate bone marrow, hepatic and renal function and willingness to provide informed consent. Patients with untreated brain metastasis were excluded. Paclitaxel (75 mg/m2) and irinotecan (50 mg/m2) were administered on days 1 & 8 of every 3-week cycle. Treatment was continued until progression up to a maximum of 6 cycles or unacceptable toxicity. The primary endpoint was response rate. Toxicity was graded by CTC version 2.0. The simon two-stage design was utilized and the estimated sample size was 55 patients (stage I - 23 patients; stage 2 - 32 patients). The study has a 90% power to detect a response rate of 30%, with an alpha error rate of 10%. Results: 55 patients have been enrolled and complete data are available for 32 patients at the time of this report. Patient baseline characteristics are: male 53%, PS 0–44%; PS 1–47% and PS 2–6%. The median age is 61 years. Fifteen patients received ≥ 4 cycles. Salient grades 3–5 toxicities seen: neutropenia (13%), fatigue (13%); diarrhea (3%), hypersensitivity (3%) and hyponatremia (3%).The objective response rate is 37% (95% CI 19%-55%) with 9 PRs and 1 CR. Additional 8 patients (24%) had stable disease. The median survival is 19.6 weeks (95% CI 15.1–29.4) and the 1-year survival rate is 15%. Conclusions: The combination of irinotecan and paclitaxel is well tolerated and has promising anti-cancer activity in recurrent SCLC. Updated data on all 55 patients will be available at the time of the presentation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. K. Owonikoko
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - S. Ramalingam
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - J. Forster
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - Y. Shuai
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - T. Evans
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - W. E. Gooding
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - M. Sulecki
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - C. P. Belani
- Univ of Pittsburgh, Pittsburgh, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA
| |
Collapse
|
18
|
Shuai Y, Xia XL, Tan HP. DIRECTION CHARACTERISTIC AND UNIFORMITY OF ENERGY IN THE FOCAL REGION OF SOLAR COLLECTOR SYSTEM. Radiation 2006. [DOI: 10.1615/ihtc13.p4.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|